Ask Warren

JONBUR Research · Update note

Bioneercorporation · 064550 · Biotech & Pharma

Bioneercorporation: Model Fair Value Estimate Cut by 67% to ₩6,119 per Share

Why this report

Written after:

  • Model fair value changeModel estimate of fair value moved -67% (₩18,543 → ₩6,119 per share)Oct 22, 2026

Our model estimate of fair value for Bioneercorporation fell 67% to a base of ₩6,119 per share from ₩18,543. The base case now sits below the latest share price of ₩7,760, reversing the picture in the previous report.

Written Oct 21, 2026 · Data as of Oct 20, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

What happened

On 2026-10-22 our valuation model's base estimate moved from ₩18,543 to ₩6,119 per share, a change of -67%. No new filings, news or holder changes are in the data to explain it, and no minor events are listed.

The model method and rate are unchanged: a 5-year discounted cash flow at 7.5%, based on trailing figures to H1 2026. The as-of period is the same as before. The data does not say which input changed, so the reason for the revision is not available. The trailing figures shown are revenue of ₩345.9B, operating income of ₩6.2B, net income of -₩6.7B and free cash flow of -₩10.1B.

What it changes for the thesis

The previous report (2026-10-18) described growing revenue with weak, uneven profitability, and said the recovery was not yet confirmed. It also warned that the model estimate depended heavily on an assumed margin recovery. The new, much lower estimate is consistent with that caution, but nothing in the data shows the business itself has changed.

Revenue growth, thin margins (trailing operating margin 1.8%, net margin -1.9%), low debt (liabilities to equity 69.7%) and falling foreign ownership (4.1% now versus 7.4% sixty days ago) all stand as before. The thesis that the next filings will decide whether the 2025 operating improvement is lasting is unchanged.

What it changes for the valuation

The updated model estimate, based on the assumptions shown, is ₩1,286 bear, ₩6,119 base and ₩14,885 bull per share. The previous estimate was ₩10,558 bear, ₩18,543 base and ₩32,015 bull. The estimate is not a target.

Against the ₩7,760 close on 2026-10-20, the base case is about 21% lower, the bear case is far lower, and only the bull case is above the price. Previously all three cases sat above the share price. The shares trade at 1.0x book value and 0.6x sales; price-to-earnings and EV/EBITDA cannot be calculated because earnings are negative. The range between bear and bull is very wide, which shows how sensitive the model is to its assumptions.

Closing view

The evidence shows a large change in a model output with no matching change in reported numbers or news that we can see. That suggests the previous estimate was fragile, and the wide new range reinforces how dependent the valuation is on assumed profit recovery. The market price now sits between the model's base and bull cases, rather than below all of them. The unexplained size of the revision means the estimate should be read with caution, and the next filings will show whether margins support either end of the range.

Model estimate of fair value

Bear
₩1,286
-82%
Base
₩6,119
-13%
Bull
₩14,885
+111%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 7.5%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

Report history

  1. Oct 21, 2026Update noteModel fair value changeBioneercorporation: Model Fair Value Estimate Cut by 67% to ₩6,119 per Share
  2. Oct 18, 2026InitiationStart of coverage (reader request)Bioneercorporation: Revenue Growth Continues While Profits Stay Thin and the Share Price Swings

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information